School of Medicine

Education & Qualifications

2^nd MB, University of Glasgow, 1967

B Sc (Hons) Biochemistry University of Glasgow 1969

Ph D in Experimental Pathology, University of Birmingham 1974

M B Ch B, University of Birmingham, 1976

MRCPath in Histopathology, University of Wales College of Medicine, 1989

Research Interests

1. Development of Sensitive Immunohistochemical & Molecular Probe Methods

2. Immunocytochemical Analysis of Thyroid Autoimmune Disease  & Neoplasia

3. Role of Metallotheionein in Cancer Development & Progression

4. Association of SV40 with Human Cancer

5. Translational Research - Biomarker Analysis in Breast Cancer & Colorectal Cancer

6. Development of Prophylactic & Immunotherapeutic Vaccines Against Cancer

Selected Recent Publications

JASANI B, WYNFORD-THOMAS D, WILLIAMS ED. Use of monoclonal anti-hapten antibodies for immunolocalisation of tissue antigens. J Clin Pathol 1981; 34: 1000-1002.

NEWMAN GR, JASANI B, WILLIAMS ED. The visualisation of trace amounts of diaminobenzidine (DAB) polymer by a novel gold-sulphide-silver method. J Microscopy 1983; 132:RP1-RP2 (rapid communication).

SCHMID KW, JASANI B, MORGAN JM, WILLIAMS ED. Light microscopic immunohistochemical demonstration of thyroid stimulating hormone (TSH) receptors on normal rat thyroid cells. J Histochem Cytochem1988; 36: 977-982.

GEE JM, AMSELGRUBER WM, JASANI B, NICHOLSON RI. Use of dinitrophenyl hapten sandwich staining procedure (DHSS) to localise oestrogen receptors in paraffin -embedded tissues. J Histochem Cytochem 1991; 39: 1659-1670.

JASANI B, THOMAS ND, NAVABI H, MILLAR DM, NEWMAN GR, GEE J, WILLIAMS ED. Dinitrophenyl (DNP) hapten sandwich staining  (DHSS) procedure. A 10 year review of its principal reagents and applications. J Immunol Methods (special edition to celebrate 25 years of immunoenzyme techniques) 1992; 50: 193-198.

NEWMAN GR, JASANI B. A new and versatile physical silver developer. Histochem J 1998; 30:635-645.

NEWMAN GR, JASANI B. Silver Development in Microscopy & Bioanalysis: Past & Present. J Pathol 1998; 186119-125.

JASANI B. Immunohistologically definable light chain restriction in autoimmune disease. J Path 1987; 154: 1-5.

SMITH C, JASANI B, WILLIAMS ED. Lambda light chain restriction in the diffuse thyroid lymphoid infiltrate in untreated Graves’ disease. In: Thyroid Autoimmunity. A. Pinchera/S.H. Ingbar/J.M. McKenzie/G.F. Fenzi (Eds) Plenum Press 1987; 335-338.

JASANI B, NEWMAN GR. Application of immunocytochemistry to thyroid tumours. In: Thyroid Tumours D. Wynford-Thomas/E.D. Williams (Eds) Churchill Livingstone 1989; 140-147.

JASANI B. Advances in Immunocytochemistry of Thyroid Tumours (1987-1994). In: Current Topics in Pathology. K. W. Schmid/W.Bocker (Eds) Springer-Verlag, Berlin Heidelberg 1997; pp 21-36.

JASANI B, ELMES ME. Immunohistochemical detection of metallothionein. In: Methods in Enzymology 1991; 205: 95-107.

SCHMID KW, ELLIS IO, GEE JMW, LEES WE, DARKE BM, KAY J, CRYER A, STARK JM, HITTMAIR A, OFNER D, DUNSER M, MARGREITER R, DAXENBICHLER G, NICHOLSON RI, BIER B, BOCKER W, JASANI B. Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasion ductal carcinoma of the breast. Virchows Archiv A Pathol Anat 1993; 422: 153-159.

JASANI B, SCHMID KW. Significance of metallothionein overexpression in human tumours. Histopathology 1997; 31:211-214.

JASANI B, CAMPBELL F, NAVABI H, SCHMID KW, WILLIAMS GT. Clonal overexpression of metallothionein is induced by somatic mutation in morphologically normal colonic mucosa. J Pathol 1998; 184:144-147.

PEPPER CJ, JASANI B, NAVABI H, WYNFORD-THOMAS D, GIBBS A. Simian Virus 40 large T-antigen (SV40LTAg) primer specific DNA amplification in human pleural mesothelioma tissue.  Thorax 1996;51:1074-1076

JASANI B, CRISTAUDO A, EMRI SA, GAZDAR AF, GIBBS A, KYNSKA B, MILLER C, MUTTI L, OHGAKI H, RADU C, TOGNON M, PROCOPIO A. Association of SV40 with human tumours. Seminars inCancer Biology. 2001; 11:49-61

Jasani B, Coleman S, Butchart E, Evans EM, Adams M, Mason M, Gibbs A, Tabi Z. Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma.Vaccine. 2005;23:2399-402.

RHODES A, JASANI B, BALATON A, et al. Study of inter-laboratory reliability and reproducibility of oestrogen and progesterone receptor assays in Europe: documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element unreliable assays. Am J Clin Pathol 2001; 115:44-58.

Jasani B, Miller K. Cell line standards to reduce HER-2/neu assay variation and the potential of automated image analysis to provide more accurate cut points for predicting clinical response to trastuzumab Am J Clin Pathol. 2005 Feb;123(2):314;

Kay E, O'Grady A, Morgan JM, Wozniak S, Jasani B.Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing. J Clin Pathol. 2004;57:1140-4.

Jasani b, Douglas-Jones a, Rhodes a, Wozniak s, Barrett-Lee p, Gee j, Nicholson r. Measurement of oestrogen receptor status by immunocytochemistry in paraffin wax sections. In: Breast Cancer Research Protocols. Section 1. Basic Pathology Techniques. 2006;120:127-46.

ADAMS M, BORYSIEWICZ L, FIANDER A, MAN S, JASANI B, NAVABI H, LIPPETZ C, EVANS AS, MASON M. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine. 2001; 19:2549-2556.

ADAMS M, JASANI B, CAMILO ALS, MASON M. Dendritic Cell Approaches to Immunotherapy. In: Cancer Vaccines and Immunotherapy. Eds: PL Stern, PLC Beverley & MW Carroll, Cambridge University Press, 2000; 237-255

Adams M, Jasani B, Fiander A.Human papilloma virus (HPV) prophylactic vaccination. Vaccine. 2007 Jan 18;

Selected Projects

Project name: Experimental Cancer Medicine Centre(co-investigator)
Funder: CR-UK
Duration: 5 Years
Value: £2.7 m
Aims: To promote Cancer translational research ‘Bench to Clinic’

Project name: Study of Biomarkers of Nephrotoxicity
Funder: DTI/AstraZeneca
Duration: 3 years
Value: £0.9 m
Aims: To evaluate antibody markers of nephrotoxicity

Project name: COIN Trial(co-investigator)
Funder: CR-UK
Duration: 3 years
Value: £0.27 m
Aims: To evaluate biomarkers of EGFRsignalling pathway in colo-rectal cancer

Project name: Tamoxifen Breast Cancer Relapse Study & Breast Cancer p53 Analysis
Funder: CR-UK
Duration: 3 Years
Value: £0.25 m